Epigenetic aberrations offer dynamic and reversible targets for cancer therapy; increasingly,
alteration via overexpression, mutation, or rearrangement is found in genes that control the …

Breast cancer is a complex disease driven by multiple factors including both genetic and
epigenetic alterations. Recent studies revealed that abnormal gene expression induced by …

The human epidermal growth factor receptor-2 (HER2/neu/ERBB2) is overexpressed in
several cancer types. Although therapies targeting the HER2/neu protein result in inhibition …

Histone deacetylase inhibitors (HDACi) are anticancer agents that induce hyperacetylation
of histones, resulting in chromatin remodeling and transcriptional changes. In addition …

Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat,
belinostat and panobinostat, have been previously shown to have a wide range of activity in …

We have previously created a potent DNA vaccine encoding calreticulin linked to the human
papillomavirus (HPV) oncogenic protein E7 (CRT/E7). While treatment with the CRT/E7 DNA …

Recepteur d'origine nantais (Ron) is overexpressed in a panel of pancreatic cancer cells
and tissue samples from pancreatic cancer patients. Ron can be activated by its ligand …

Histone deacetylases (HDACs) play important roles in fundamental cellular processes, and
HDAC inhibitors are emerging as promising cancer therapeutics. p73, a member of the p53 …

Since the last edition of this book, major advances have been made in our understanding of
key pathways that control tumor progression. This has led to the development of new …

ATP-dependent nucleosome repositioning by chromatin remodeling enzymes requires the
translocation of these enzymes along the nucleosomal DNA. Using a fluorescence stopped …